PLK4

Across TCGA pan-cancer cohorts, PLK4 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PLK4 data layer compared with 26 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher PLK4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PLK4 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

HNSC, UCEC, and LIHC are the cancer types where PLK4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	III,IV	0.172	0.748	<.001	24	view →
UCEC	DFS	Median	II,III,IV	1.000	0.440	.018	24	view →
LIHC	DFS	Median	All	0.126	0.545	.003	21	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LUAD	OS	Median	III,IV	0.294	0.666	.031	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PLK4–HNSC (OS)

Open the HNSC breakdown →